United States v. Canori

737 F.3d 181, 2013 WL 6246354, 2013 U.S. App. LEXIS 24099
CourtCourt of Appeals for the Second Circuit
DecidedDecember 4, 2013
Docket12-4837-cr
StatusPublished
Cited by29 cases

This text of 737 F.3d 181 (United States v. Canori) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Canori, 737 F.3d 181, 2013 WL 6246354, 2013 U.S. App. LEXIS 24099 (2d Cir. 2013).

Opinion

JOSÉ A. CABRANES, Circuit Judge:

Defendant Eric Canori appeals from the judgment of the District Court for the Northern District of New York (Gary L. Sharpe, Chief Judge), entered November 27, 2012, sentencing him principally to thirty months’ imprisonment after he pleaded guilty to conspiracy to distribute and to possess with intent to distribute 100 or more kilograms of marijuana in violation of 21 U.S.C. §§ 846 and 841(a)(1). 1 As part of his plea agreement, Canori reserved his right to appeal the District Court’s denial of his motion to dismiss the indictment. In that motion, and now on appeal, Canori contends that an October 2009 memorandum issued by Deputy Attorney General David W. Ogden of the U.S. Department of Justice (the “Ogden Memo”) created a de facto “rescheduling” 2 of marijuana under the Controlled Substances Act (“CSA”), 21 U.S.C. §§ 801 et seq., such that he cannot validly be charged with conspiracy to distribute marijuana. Canori further argues that, because marijuana has been de facto rescheduled, his conviction violated his rights under the Due Process and Equal Protection Clauses of the United States Constitution, and his constitutional right to the effective assistance of counsel.

DISCUSSION

Canori moved to dismiss his indictment on the basis that the Ogden Memo led to a de facto rescheduling of marijuana, such that it was no longer a Schedule I drug under the CSA. In its Memorandum-Decision and Order dated January 25, 2011, the District Court rejected this argument as “wholly without merit.” We review a district court’s denial of a motion to dismiss an indictment de novo. See, e.g., United States v. Daley, 702 F.3d 96, 99-100 (2d Cir.2012); United States v. Yannotti, 541 F.3d 112, 121 (2d Cir.2008). For the reasons stated below, we agree with the District Court.

A. Statutory Scheme

The CSA “creates a comprehensive, closed regulatory regime criminalizing the unauthorized manufacture, distribution, dispensing, and possession of substances classified in any of the Act’s five schedules.” Gonzales v. Oregon, 546 U.S. 243, 250, 126 S.Ct. 904, 163 L.Ed.2d 748 (2006) (citations omitted). The CSA organizes substances into fives schedules based on (1) their potential for abuse, (2) their accepted medical uses, and (3) their accepted safety for use under medical supervision and potential for psychological or physical dependence. See 21 U.S.C. § 812. Sched *183 ule I, 3 in which marijuana is expressly classified, see id. Schedule I(c)(10), contains the most severe restrictions on use, the violation of which may result in criminal penalties, see id. § 841(b). We have previously upheld the constitutionality of Congress’s classification of marijuana as a Schedule I drug. See United States v. Kiffer, 477 F.2d 349, 355-57 (2d Cir.1973).

The scheduling of controlled substances under the CSA is not static. Not only can Congress amend it, but the statute itself includes a provision permitting the Attorney General to add or transfer a drug to a particular schedule if he “(A) finds that such drug or other substance has a potential for abuse, and (B) makes with respect to such drug or other substance the [requisite findings, see note 3, ante ] for the schedule in which such drug is to be placed.” Id. § 811(a)(1). 4 The CSA mandates that such a reclassification by the Attorney General be made “on the record after opportunity for a hearing pursuant to the rulemaking procedures prescribed by [the Administrative Procedure Act CAPA’) at 5 U.S.C. § 553].” Id. § 811(a). In assessing the scientific and medical factors relevant to this rulemaking process, the Attorney General is required to request an evaluation from the Secretary of Health and Human Services, and accept the findings contained in the evaluation as binding. Id. § 811(b); see also Gonzales, 546 U.S. at 250, 126 S.Ct. 904.

B. Ogden Memo

On October 19, 2009, Deputy Attorney General Ogden issued a “Memorandum for Selected United States Attorneys.” The Ogden Memo acknowledges that some States have enacted laws authorizing the medical use of marijuana, and it provides guidance to U.S. Attorneys within those States as to how to exercise their prosecu-torial discretion consistent with Department of Justice priorities. Specifically, the Memo states that, while “[t]he prosecution of significant traffickers of illegal drugs, including marijuana, ... continues to be a core priority,” U.S. Attorneys “[a]s a general matter ... should not focus federal resources in [their] States on individuals whose actions are in clear and unambiguous compliance with existing state laws providing for the medical use of marijuana.” Accordingly, the Memo advises that prosecutors focus their resources on illegal drug trafficking activity (including marijuana) involving factors such as firearms, violence, sales to minors, and significant amounts of marijuana, i.e., factors that are inconsistent with compliance with applicable state law. Notably, however, the Memo does not purport to legalize or reclassify marijuana:

[T]his memorandum does not alter in any way the Department’s authority to enforce federal law, including laws prohibiting the manufacture, production, distribution, possession, or use of marijuana on federal property. This guidance regarding resource allocation does not “legalize” marijuana or provide a legal defense to a violation of federal law, nor is it intended to create any *184 privileges, benefits, or rights, substantive or procedural, enforceable by any individual, party or witness in any administrative, civil, or criminal matter. Nor does clear and unambiguous compliance with state law or the absence of one or all of the above factors create a legal defense to a violation of the Controlled Substances Act. Rather, this memorandum is intended solely as a guide to the exercise of investigative and prosecutorial discretion.

Ogden Memo 2 (emphasis supplied).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kornea v. Miller
S.D. New York, 2025
Cannabis Impact Prevention Coalition, LLC v. New York State Cannabis Control Bd.
2025 NY Slip Op 25045 (New York Supreme Court, Albany County, 2025)
Peridot Tree, Inc. v. City of Sacramento
94 F.4th 916 (Ninth Circuit, 2024)
United States v. Jerry Haymon
Fourth Circuit, 2021
United States v. Cosme
Second Circuit, 2021
United States v. Dawkins, Code
999 F.3d 767 (Second Circuit, 2021)
United States v. Smilowitz
974 F.3d 155 (Second Circuit, 2020)
Crimson Galeria Ltd. v. Healthy Pharms, Inc.
337 F. Supp. 3d 20 (District of Columbia, 2018)
STEVEN KADONSKY VS. STEVE C. LEE (Division of Consumer Affairs)
New Jersey Superior Court App Division, 2017
Arthur West v. Loretta E. Lynch
845 F.3d 1228 (D.C. Circuit, 2017)
United States v. Strong, Jr.
Second Circuit, 2016
United States v. Strong
844 F.3d 133 (Second Circuit, 2016)
United States v. Filippi
622 F. App'x 25 (Second Circuit, 2015)
United States v. William Johnson
628 F. App'x 124 (Third Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
737 F.3d 181, 2013 WL 6246354, 2013 U.S. App. LEXIS 24099, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-canori-ca2-2013.